Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cigna (CI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Cigna (CI) Soars 6.3%: Is Further Upside Left in the Stock?

Humana

The healthcare industry, particularly PBMs, faces bipartisan scrutiny, leading to significant stock declines for Humana and Cigna, presenting a contrarian investment opportunity. President-elect Donald Trump's stance on PBMs and bipartisan legislative proposals signal potential regulatory changes, creating market uncertainty for PBM-affiliated companies. Despite recent financial setbacks, Cigna and Humana show strong revenue growth, with investment losses and rising benefit costs impacting short-term profitability.

Humana, Cigna Plunge On Trump's Latest Promise: A Potential Buying Opportunity?

CVS Health

UnitedHealth Group

Shares in major healthcare companies fell yesterday after president-elect Donald Trump made comments that he wanted to “knock out” prescription drug industry middlemen. The fall makes this yet another week since the killing of UnitedHealth CEO Brian Thompson that the business practices of companies that operate America's private healthcare system have come under increased scrutiny.

UnitedHealth, CVS, and Cigna stock prices take another hit after Trump says he's going to ‘knock out' drug industry middlemen

Eli Lilly

Pfizer

Shares of health insurers operating pharmacy benefit managers fell on Monday after U.S. President-elect Donald Trump called them middlemen who drive up costs and said he plans to eliminate their role.

Insurer stocks fall after Trump says 'we're going to knock out the middleman'

Cigna's strong fundamentals, including consistent revenue and EPS growth, a solid balance sheet, and undervalued stock price, support a buy rating. The company's Q3 results showed a 29.9% revenue increase and a 10.9% rise in non-GAAP EPS, driven by customer growth and price hikes. Cigna's dividend yield and growth potential are robust, with a low payout ratio and projected double-digit annual EPS growth supporting future dividend increases.

Cigna: I'm Loading Up On This Dividend Growth Stock Now

Johnson & Johnson

Johnson & Johnson has sued divisions of Cigna , accusing the health insurer of working with a drug-benefit middleman to drain J&J's financial-assistance funds earmarked for patients taking some of its pricier drugs, The Wall Street Journal reported on Friday.

J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Cigna (CI) is a Strong Value Stock

One influential healthcare analyst says the chances of such a bill passing are less than 5%.

Cigna's stock leads selloff among drug middlemen on breakup fears — but this analyst says it's not a real risk

Centene

Elevance Health Inc

Shares of major healthcare companies fell nearly 5% on Wednesday on concerns related to potential changes to their complex business models. That includes UnitedHealth Group, Cigna and CVS Health, which operate three of the nation's largest private health insurers and drug supply chain middlemen called pharmacy benefit managers.

Health care stocks fall as lawmakers, patients push for changes to their business models

Shares of health insurers such as UnitedHealth and CVS Health fell on Wednesday after a Wall Street Journal report said a bipartisan group of lawmakers were set to introduce legislation to break up pharmacy-benefit managers.

Health insurer stocks fall as WSJ says lawmakers set to break up pharmacy-benefit managers

Major insurance stocks have fallen more than 6% since their closing prices last Tuesday, the day before the deadly shooting of Brian Thompson, the CEO of UnitedHealth Group's insurance arm. That includes UnitedHealth Group, CVS Health and Cigna, which operate three of the nation's largest private health insurers.

Insurance stocks have fallen since UnitedHealthcare CEO's killing

Archer-Daniels-Midland Company

Automatic Data Processing

Ares Capital

Atmos Energy

Broadcom

American Express

Bank of America

British American Tobacco

Celanese

Carlisle Companies

Cintas Corp

Coterra Energy

Dick's Sporting Goods

Dow Inc

Enbridge

EOG Resources

Gaming and Leisure Properties

Huntington Ingalls Industries

Lennar

Lam Research

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3.28%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 9%.

5 Relatively Secure And Cheap Dividend Stocks For December 2024: Yields Up To 9%

Thompson's death sparked a wide social media conversation over frustrations with navigating the US health insurance system.

UnitedHealth, rival insurer stocks continue to tumble after Brian Thompson's murder in NYC

Shares of health insurance companies including UnitedHealth Group continued to fall on Friday, two days after Brian Thompson, the CEO of the company's health insurance unit, was fatally shot outside a Manhattan hotel by a gunman lying in wait.

Health insurer shares fall after UnitedHealth exec murder

Shares of UnitedHealthcare's parent company led a broader selloff in health insurance stocks, losses one analyst described as a likely result of the industry's fresh focus following the Wednesday killing of UnitedHealthcare's chief executive Brian Thompson.

Health Insurance Stocks—Led By UnitedHealth—Suffer Steep Drops Following Brian Thompson's Killing

Extra Space Storage

L3Harris

Many people, especially under 45, are falling behind in retirement savings due to financial crises, student debt, and high living expenses. Investing is crucial to combat inflation and benefit from stock market gains, even if it requires significant sacrifices. Index funds like the S&P 500 or high-quality dividend ETFs are recommended for most investors, but knowledgeable investors might consider specific dividend stocks.

Escape The 9-5 Grind: 3 Terrific Dividend Stocks To Fuel Your Financial Freedom

CI is well-poised for growth on the back of strong contributions from the Evernorth and Cigna Healthcare units. A strong financial position enables it to undertake business investments.

Here's Why Retaining Cigna Stock is a Smart Move for Investors Now

New grant program to support 15 nonprofits focused on addressing health disparities in Hartford, CT, and Houston, TX BLOOMFIELD, Conn. , Nov. 26, 2024 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), announced today the first round of grant recipients – comprised of 15 nonprofits across Hartford, CT, and Houston, TX – for The Cigna Group Health Equity Impact Fund.

The Cigna Group Foundation Announces First Grantee Cohort of Health Equity Impact Fund

CVS Health, UnitedHealth Group and Cigna sued the Federal Trade Commission, claiming the agency's case against drug middlemen over high insulin prices in the U.S. is unconstitutional.  The complaint is the latest move in a bitter legal fight between the three largest pharmacy benefit managers, or PBMs, in the U.S. and the FTC.

CVS, UnitedHealth, Cigna sue to block FTC case over insulin prices

CI reaffirms its 2024 outlook, projecting full-year adjusted EPS to be a minimum of $28.40.

Cigna Ends Humana Merger Speculation: CI Jumps 7.3% While HUM Slips

The healthcare company put merger rumors to bed.

Why Cigna Stock Popped Today

The Cigna Group confirmed “it is not pursuing a combination with Humana.”

Why Cigna Deal With Humana Made Little Sense To Begin With

Shares of Humana Inc (NYSE:HUM) are down 3.7% at $277.38 at last glance, after Cigna Group (NYSE:CI) said it was not pursuing a merger with the smaller health insurance name, and will instead prioritize share buybacks.

2 Healthcare Stocks in Focus After Merger Talks Break Down

US health insurer Cigna has made the appropriate decision to ditch plans to merge with rival Humana (NYSE:HUM), if today's market reaction is anything to go by. Rumours of the merger, which would have created a $140 billion insurance behemoth, began circulating last December, but doubts over the deal quickly followed.

Cigna rallies after Humana mega-merger called off

Investors have long appeared skeptical about a potential merger between the two health insurers.

News for Cigna Stock (CI)